The way I am reading/interpreting the second sentence in the paragraph below is just management noting that investors should not expect HLTT's other businesses (Medi-Scan, RevHeart, and future acquisitions) to generate revenue as quickly as the wound care business has. This particular acquisition was just somewhat unique in that they were able to acquire a product/technology/business in an advanced stage of development and get the product approved/marketed in a more compressed timeline than we should normally expect. An "exception to the norm".......
I would be somewhat surprised if HLTT's Q4 revenue was not fairly decent/sizable. The wound care business showed about a $351K loss in Q3, which means operating expenses for that business were about $1.075M in the third quarter. It is very possible those operating expenses can be reduced in Q4, but I think the revenue number will still need to be reasonably high for the business to reach profitability.
Twice in the Q3 report, the company mentions an expectation of the wound care business reaching a profitable status in the near-term......
The Q3 was filed in the last week of November, with almost 2 months of Q4 completed. I would assume management would not have provided that kind of guidance and timeline unless the numbers/projections they were seeing looked favorable.